Back to Search
RAJA PERNI, M.D.
M.D.
Psychiatry Physician
NPI: 1619086279Individual
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
4301407620(MI)
Research & Publications (20)
Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators.
PMID 19303289·Bioorg Med Chem Lett·2009
4-observational
Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3.
PMID 19241369·Protein Sci·2009
7-preclinical
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
PMID 19199480·J Med Chem·2009
7-preclinical
Crystal structures of human SIRT3 displaying substrate-induced conformational changes.
PMID 19535340·J Biol Chem·2009
8-other
Discovery of benzothiazole derivatives as efficacious and enterocyte-specific MTP inhibitors.
PMID 19181526·Bioorg Med Chem Lett·2009
4-observational
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
PMID 18046409·Nature·2007
7-preclinical
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
PMID 17482818·Bioorg Med Chem Lett·2007
7-preclinical
VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
PMID 16641454·Antimicrob Agents Chemother·2006
4-observational
Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
PMID 17002221·Curr Opin Drug Discov Devel·2006
6-review
Hydrogenation of aromatic ketones, aldehydes, and epoxides with hydrogen and Pd(0)EnCat 30NP.
PMID 16934142·Beilstein J Org Chem·2006
8-other
Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
PMID 16787300·Infect Disord Drug Targets·2006
6-review
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
PMID 16495249·Antimicrob Agents Chemother·2006
4-observational
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
PMID 16087668·J Biol Chem·2005
4-observational
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
PMID 15050632·Bioorg Med Chem Lett·2004
8-other
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
PMID 15006379·Bioorg Med Chem Lett·2004
8-other
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
PMID 14766754·J Biol Chem·2004
8-other
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.
PMID 14592508·Bioorg Med Chem Lett·2003
8-other
Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy.
PMID 12536674·Prog Med Chem·2002
6-review
NS3.4A protease as a target for interfering with hepatitis C virus replication.
PMID 12937632·Drug News Perspect·2000
8-other
Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.
PMID 11128652·Bioorg Med Chem Lett·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4646 JOHN R ST
DETROIT, MI 48201 - Phone
- (313) 576-1000
Quick Facts
- NPI
- 1619086279
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile